# A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer

> **NCT04053205** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 76 (estimated)

## Conditions studied

- Advanced Gastric or Gastroesophageal Junction Cancer

## Interventions

- **DRUG:** Gentuximab
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT04053205
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08
- **Primary completion:** 2020-06
- **Final completion:** 2020-12
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2019-08-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04053205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04053205, "A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04053205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*